{
  "ticker": "EMD",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959566",
  "id": "02959566",
  "pages": 9,
  "price_sensitive": false,
  "date": "20250618",
  "time": "0944",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250618/pdf/06kvr5gz5mt7w0.pdf",
  "summary": "### Capital Raising Announcement Summary:  \n- **Structure**: Placement with attaching options  \n- **Total Capital Raised**:  \n  - **Ordinary Shares**: 166,666,667 new shares issued at **AUD 0.024** per share.  \n  - **Options**:  \n    - 55,555,556 unquoted options (attaching to Placement Shares, 1:3 ratio) \u2013 Exercise price **AUD 0.05**, expiry **18 Feb 2027**.  \n    - 2,500,000 unquoted options (issued to Lead Manager) \u2013 Same terms as above.  \n    - 2,083,333 unquoted options (issued for investor relations services) \u2013 Same terms as above.  \n- **Timetable**:  \n  - **Proposed Issue Date**: 25 June 2025.  \n  - **Shareholder Approval Deadline**: 18 August 2025 (for Tranche 2 shares and options).  \n- **Use of Proceeds**: Fund expanded treatment programs (including Medibank agreement) and working capital.  \n- **Fees**: Lead Manager (GBA Capital) receives 2-4% fees + 2.5M options.  \n- **Placement Capacity**:  \n  - 71,290,790 shares issued under 15% capacity (no approval required).  \n  - 48,916,082 shares issued under 10% capacity (no approval required).  \n\n**Key Impact**: Significant dilution (172.9M+ new shares + 60M+ options) at a deep discount to current market price.",
  "usage": {
    "prompt_tokens": 3927,
    "completion_tokens": 335,
    "total_tokens": 4262,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-17T23:51:25.320964"
}